论文部分内容阅读
目的观察紫杉醇腹腔内灌注对治疗恶性腹水的近期疗效。方法 18例恶性腹水患者随机、双盲分为紫杉醇组和顺铂组,采用对照研究,分别于腹腔积液尽量排净后,给予腹腔内灌注紫杉醇或顺铂。每周1次,连续3周。结果紫杉醇组临床总有效率为88.9%,顺铂组临床总有效率为55.6%,两组相比差异具有统计学意义(P<0.05)。紫杉醇组生活质量改善较顺铂组明显,两组药物不良反应差异无统计学意义(P>0.05)。结论腹腔内灌注紫杉醇治疗恶性腹水近期疗效较好,操作简单方便、不良反应少,是一种前景较好的治疗方法。
Objective To observe the short-term efficacy of paclitaxel intraperitoneal perfusion in the treatment of malignant ascites. Methods 18 patients with malignant ascites were randomly divided into two groups: paclitaxel group and cisplatin group. The control group was given intraperitoneal injections of paclitaxel or cisplatin respectively after the ascites were drained. Once a week for 3 weeks. Results The total clinical effective rate was 88.9% in the paclitaxel group and 55.6% in the cisplatin group. The difference between the two groups was statistically significant (P <0.05). The quality of life in paclitaxel group was significantly improved compared with that in cisplatin group. There was no significant difference in adverse drug reaction between the two groups (P> 0.05). Conclusion Intraperitoneal injection of paclitaxel in the treatment of malignant ascites has a better curative effect in the near future. It is simple and convenient to operate and has few adverse reactions. It is a promising treatment.